# Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

> **NCT02345707** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 37 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** Cabotegravir 30 mg current formulation
- **DRUG:** Cabotegravir 30 mg micronized new formulation 500 M
- **DRUG:** Cabotegravir 30 mg unmicronized new formulation 500 U
- **DRUG:** Cabotegravir 30 mg micronized new formulation 650 M
- **DRUG:** Cabotegravir 30 mg unmicronized new formulation 650 U

## Key facts

- **NCT ID:** NCT02345707
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345707, "Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02345707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*